Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Immunovant ends cutaneous lupus program after phase 2 flop

Immunovant ends cutaneous lupus program after phase 2 flop

  • September 23, 2026

Immunovant has stopped development of IMVT-1402 in cutaneous lupus erythematosus after failing a midphase test, closing off one path to market for the anti-FcRn antibody.

Leave A Comment

Fields (*) Mark are Required